Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXI-002 T Cells in Relapsed/Refractory Multiple Myeloma
NCT04505813Phase 2Suspended
- Sponsor
- NexImmune, Inc.
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NEXI-002 in multiple myeloma (MM), sponsored by NexImmune, Inc.. Started Aug 2020; status: suspended.
02
Drugs
NEXI-002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04505813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505813.